About vor biopharma inc - VOR
Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.
VOR At a Glance
Vor Biopharma, Inc.
500 Boylston Street
Boston, Massachusetts 02116
| Phone | 1-617-655-6580 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -695,981,000.00 | |
| Sector | Health Technology | Employees | 76 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
VOR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.876 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.009 |
VOR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -9,157,644.737 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VOR Liquidity
| Current Ratio | 18.20 |
| Quick Ratio | 18.20 |
| Cash Ratio | 18.085 |
VOR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -225.228 |
| Return on Equity | N/A |
| Return on Total Capital | 431.45 |
| Return on Invested Capital | N/A |
VOR Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -1.86 |
| Total Debt to Total Assets | 0.645 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -1.686 |